100 related articles for article (PubMed ID: 26824268)
1. An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice.
Abdolvahab MH; Fazeli A; Radmalekshahi M; Nejadnik MR; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Mar; 36(3):192-203. PubMed ID: 26824268
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates.
Abdolvahab MH; Fazeli A; Halim A; Sediq AS; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Apr; 36(4):247-57. PubMed ID: 26835734
[TBL] [Abstract][Full Text] [Related]
3. Effect of arginine on pre-nucleus stage of interferon beta-1b aggregation.
Fazeli A; Haji-Abdolvahab M; Shojaosadati SA; Schellekens H; Khalifeh K; Moosavi-Movahedi AA; Fazeli MR
AAPS PharmSciTech; 2014 Dec; 15(6):1619-29. PubMed ID: 25142823
[TBL] [Abstract][Full Text] [Related]
4. Development of a transgenic mouse model immune tolerant for human interferon Beta.
Hermeling S; Jiskoot W; Crommelin D; Bornaes C; Schellekens H
Pharm Res; 2005 Jun; 22(6):847-51. PubMed ID: 15948027
[TBL] [Abstract][Full Text] [Related]
5. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.
van Beers MM; Sauerborn M; Gilli F; Hermeling S; Brinks V; Schellekens H; Jiskoot W
J Immunol Methods; 2010 Jan; 352(1-2):32-7. PubMed ID: 19857496
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.
Hermeling S; Aranha L; Damen JM; Slijper M; Schellekens H; Crommelin DJ; Jiskoot W
Pharm Res; 2005 Dec; 22(12):1997-2006. PubMed ID: 16184451
[TBL] [Abstract][Full Text] [Related]
7. The effects of dodecyl maltoside and sodium dodecyl sulfate surfactants on the stability and aggregation of recombinant interferon Beta-1b.
Haji Abdolvahab M; Fazeli A; Fazeli MR; Brinks V; Schellekens H
J Interferon Cytokine Res; 2014 Nov; 34(11):894-901. PubMed ID: 24956236
[TBL] [Abstract][Full Text] [Related]
8. The role of trehalose for metastable state and functional form of recombinant interferon beta-1b.
Fazeli A; Shojaosadati SA; Fazeli MR; Khalifeh K; Ariaeenejad S; Moosavi-Movahedi AA
J Biotechnol; 2013 Feb; 163(3):318-24. PubMed ID: 23183384
[TBL] [Abstract][Full Text] [Related]
9. [Solubilization Specificities Interferon beta-1b from Inclusion Bodies].
Zhuravko AS; Kononova NV; Bobruskin AI
Bioorg Khim; 2015; 41(4):403-10. PubMed ID: 26615635
[TBL] [Abstract][Full Text] [Related]
10. The Rebif new formulation story: it's not trials and error.
Jaber A; Driebergen R; Giovannoni G; Schellekens H; Simsarian J; Antonelli M
Drugs R D; 2007; 8(6):335-48. PubMed ID: 17963425
[TBL] [Abstract][Full Text] [Related]
11. Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation.
Mahjoubi N; Fazeli MR; Dinarvand R; Khoshayand MR; Fazeli A; Taghavian M; Rastegar H
Adv Pharm Bull; 2015 Nov; 5(4):497-505. PubMed ID: 26819922
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation.
Hermeling S; Schellekens H; Maas C; Gebbink MF; Crommelin DJ; Jiskoot W
J Pharm Sci; 2006 May; 95(5):1084-96. PubMed ID: 16552750
[TBL] [Abstract][Full Text] [Related]
13. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
[TBL] [Abstract][Full Text] [Related]
14. Functional Deimmunization of Interferon Beta-1b by Identifying and Silencing Human T Cells Epitopes.
Moradi Hasan-Abad A; Adabi E; Sadroddiny E; Khorramizadeh MR; Mazlomi MA; Mehravar S; Kardar GA
Iran J Allergy Asthma Immunol; 2019 Aug; 18(4):427-440. PubMed ID: 31522451
[TBL] [Abstract][Full Text] [Related]
15. Development of a high performance size exclusion chromatography method to determine the stability of Human Serum Albumin in a lyophilized formulation of Interferon alfa-2b.
Qian J; Tang Q; Cronin B; Markovich R; Rustum A
J Chromatogr A; 2008 Jun; 1194(1):48-56. PubMed ID: 18258245
[TBL] [Abstract][Full Text] [Related]
16. Production, purification, and chemical stability of recombinant human interferon-γ in low oxygen tension condition: a formulation approach.
Malek-Sabet N; Masoumian MR; Zeinali M; Khalilzadeh R; Mousaabadi JM
Prep Biochem Biotechnol; 2013; 43(6):586-600. PubMed ID: 23742090
[TBL] [Abstract][Full Text] [Related]
17. In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.
Scagnolari C; Selvaggi C; Di Biase E; Fraulo M; Dangond F; Antonelli G
J Immunoassay Immunochem; 2014; 35(3):288-99. PubMed ID: 24654824
[TBL] [Abstract][Full Text] [Related]
18. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
19. Potency stability of recombinant (Serine-17) human interferon-beta.
Geigert J; Ziegler DL; Panschar BM; Creasey AA; Vitt CR
J Interferon Res; 1987 Apr; 7(2):203-11. PubMed ID: 3039014
[TBL] [Abstract][Full Text] [Related]
20. A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta.
Abdolvahab MH; Brinks V; Schellekens H
J Immunol Methods; 2014 Dec; 415():17-23. PubMed ID: 25450255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
